Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
7
88%
Ph phase_3
1
13%

Phase Distribution

7

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
7(87.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (87.5%)
Phase 31 (12.5%)

Trials by Status

completed675%
terminated113%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_1

An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

NCT00880061
completedphase_1

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

NCT00024570
withdrawnphase_1

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

NCT00378235
completedphase_1

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

NCT00089427
completedphase_1

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

NCT00064779
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00880061Phase 1

An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

Terminated
NCT00024570Phase 1

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

Completed
NCT00378235Phase 1

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Withdrawn
NCT00089427Phase 1

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Completed
NCT00064779Phase 1

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

Completed
NCT00024557Phase 1

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Completed
NCT00041587Phase 1

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

Completed
NCT00076986Phase 3

The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8